Bayer joins transparency push

Bayer HealthCare has joined the transparency movement. The drugmaker is the latest to announce that it, too, was making de-identified clinical trial information available to approved researchers. Boehringer Ingelheim announced a similar policy earlier this week.

Bayer said in a statement that its decision is in support of the European Medicines Agency's efforts to increase access to clinical trial data, and noted that “as a member of the pharmaceutical trade associations EFPIA and PhRMA, Bayer is following their declared principles on responsible clinical trial data sharing.”

As with BI, an independent panel will grant or deny data access.

You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.